Targeting NAD+ Synthesis to Potentiate CD38-Based Immunotherapy of Multiple Myeloma.
Trends Cancer
; 6(1): 9-12, 2020 01.
Article
em En
| MEDLINE
| ID: mdl-31952784
ABSTRACT
Antibodies targeting CD38, a NAD+-degrading enzyme, have emerged as a promising immunotherapy against multiple myeloma (MM). Currently, the mechanisms by which anti-CD38 antibodies establish their therapeutic effects are poorly understood. Here, we advocate for the depletion of NAD+ to enhance the efficacy of anti-CD38-based immunotherapies in MM.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Glicoproteínas de Membrana
/
Protocolos de Quimioterapia Combinada Antineoplásica
/
Citocinas
/
ADP-Ribosil Ciclase 1
/
Nicotinamida Fosforribosiltransferase
/
Mieloma Múltiplo
/
NAD
Idioma:
En
Revista:
Trends Cancer
Ano de publicação:
2020
Tipo de documento:
Article
País de afiliação:
Canadá